These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1385 related articles for article (PubMed ID: 22341567)
21. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach. Bukowski RM Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. Hutson TE; Davis ID; Machiels JP; De Souza PL; Rottey S; Hong BF; Epstein RJ; Baker KL; McCann L; Crofts T; Pandite L; Figlin RA J Clin Oncol; 2010 Jan; 28(3):475-80. PubMed ID: 20008644 [TBL] [Abstract][Full Text] [Related]
23. [Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas]. Gennigens C; Jerusalem G Rev Med Liege; 2012; 67(7-8):437-42. PubMed ID: 22984765 [TBL] [Abstract][Full Text] [Related]
24. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Rini BI; Weinberg V; Dunlap S; Elchinoff A; Yu N; Bok R; Simko J; Small EJ Cancer; 2006 Feb; 106(3):566-75. PubMed ID: 16369983 [TBL] [Abstract][Full Text] [Related]
26. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas. Kasper B; Hohenberger P Future Oncol; 2011 Dec; 7(12):1373-83. PubMed ID: 22112314 [TBL] [Abstract][Full Text] [Related]
27. Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors. Melichar B; Studentová H; Zezulová M J BUON; 2011; 16(2):203-9. PubMed ID: 21766486 [TBL] [Abstract][Full Text] [Related]
28. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study. Mosca A; De Giorgi U; Procopio G; Basso U; Cartenì G; Bersanelli M; Naglieri E; Galli L; Caffo O; Fornarini G; Boccardo F; Porta C Jpn J Clin Oncol; 2021 Mar; 51(3):484-491. PubMed ID: 33212499 [TBL] [Abstract][Full Text] [Related]
29. Pazopanib: a review of its use in the management of advanced renal cell carcinoma. McCormack PL Drugs; 2014 Jul; 74(10):1111-25. PubMed ID: 24935162 [TBL] [Abstract][Full Text] [Related]
31. Sorafenib for the treatment of advanced renal cell carcinoma. Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398 [TBL] [Abstract][Full Text] [Related]
32. Pazopanib, a new therapy for metastatic soft tissue sarcoma. Verweij J; Sleijfer S Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774 [TBL] [Abstract][Full Text] [Related]
33. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Shih T; Lindley C Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999 [TBL] [Abstract][Full Text] [Related]
34. Treatment of metastatic renal cell carcinoma. Reeves DJ; Liu CY Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348 [TBL] [Abstract][Full Text] [Related]
35. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. Kim JH; Park I; Lee JL Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136 [TBL] [Abstract][Full Text] [Related]